October 20, 2005Open Access

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Piccart et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d7b52fb843b2be99490759 — DOI: https://doi.org/10.1056/nejmoa052306

Authors

Martine Piccart

Marion Procter

Brian Leyland‐Jones

Journals

New England Journal of Medicine

Actions

Institutions

Dana-Farber Cancer Institute

McGill University

Ludwig-Maximilians-Universität München

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion